{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:04:43Z","timestamp":1768262683536,"version":"3.49.0"},"reference-count":25,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>To evaluate the outcomes of active surveillance (AS) strategy for patients with favorable risk prostate cancer (PCa) and identify multiparametric MRI role and PCa progression predictors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method:<\/jats:title>\n            <jats:p>This was a 5-year follow-up cohort study which enrolled 153 favorable-risk PCa patients in an AS program from April 2017 to February 2023. Patients were included in this study based on AS protocol inclusion criteria. MpMRI was also a part of this protocol. Active surveillance outcomes such as adherence to AS treatment strategy and the oncologic outcomes were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>During the 4.23\u2009\u00b1\u20090.5\u2009years follow-up, 39 of 153 patients left the AS protocol by their own decision (14) or other physicians\u2019 advice, due to the concern of cancer progression; 5 of 153 died from another cause other than PCa; 9 of 153 revealed cancer progression during this time and underwent radical prostatectomy; The remaining 100 patients stayed on the AS protocol during the follow up. Adherence to AS strategy protocol was 60.55% in our study. Older age, positive family history for PCa, initial clinical stage, higher total PSA, greater PSA density, more positive cores, and greater core involvement were the most common predictors for progression. The sensitivity, specificity, positive predictive value, and negative predictive value of mpMRI for cancer progression detection were 55.55%, 97%, 62.25%, and 96%, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>AS can be a suitable alternative treatment for low-risk and very low risk prostate cancer to avoid the probable complications of radical prostatectomy. MpMRI is valid and reliable for identifying PCa progression and provides useful information when combined with biopsy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1177\/03915603251322577","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:15:53Z","timestamp":1740467753000},"page":"282-287","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Active surveillance in low risk prostate cancer: Role of multiparametric MRI and cancer progression predictors"],"prefix":"10.1177","volume":"92","author":[{"given":"Nasser","family":"Simforoosh","sequence":"first","affiliation":[{"name":"Shahid Labbafinejad Medical Center, The Center of Excellence in Urology, Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3550-3778","authenticated-orcid":false,"given":"Mehdi","family":"Dadpour","sequence":"additional","affiliation":[{"name":"Shahid Labbafinejad Medical Center, The Center of Excellence in Urology, Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-0055","authenticated-orcid":false,"given":"Behzad","family":"Narouie","sequence":"additional","affiliation":[{"name":"Department of Urology, Zahedan University of Medical Sciences, Zahedan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Hamidi","family":"Madani","sequence":"additional","affiliation":[{"name":"Shahid Labbafinejad Medical Center, The Center of Excellence in Urology, Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"issue":"3","key":"e_1_3_2_2_2","first-page":"218","article-title":"Prevalence of prostate cancer and its risk factors: results of the first phase of Shahedieh cohort study in Yazd Province, Iran","volume":"9","author":"Momayyezi M","year":"2022","unstructured":"Momayyezi M, Dehghani Tafti A, Keyghobadi N, et al. Prevalence of prostate cancer and its risk factors: results of the first phase of Shahedieh cohort study in Yazd Province, Iran. J Prev Med. 2022; 9(3): 218\u2013229.","journal-title":"J Prev Med"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2017.0320"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02808"},{"issue":"12","key":"e_1_3_2_6_2","first-page":"915","article-title":"Secondary cancers during the radiotherapy of prostate cancer: a review article","volume":"79","author":"Zoljalali Moghaddam SH","year":"2022","unstructured":"Zoljalali Moghaddam SH, Laripour R, Hazrati E, et al. Secondary cancers during the radiotherapy of prostate cancer: a review article. Teh Uni Med J. 2022; 79(12): 915\u2013924.","journal-title":"Teh Uni Med J"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"issue":"2","key":"e_1_3_2_8_2","first-page":"162","article-title":"Cytoreductive and palliative radical prostatectomy, extended lymphadenectomy and bilateral orchiectomy in advanced prostate cancer with oligo and widespread bone metastases: result of a feasibility, our initial experience","volume":"16","author":"Simforoosh N","year":"2019","unstructured":"Simforoosh N, Dadpour M, Mofid B. Cytoreductive and palliative radical prostatectomy, extended lymphadenectomy and bilateral orchiectomy in advanced prostate cancer with oligo and widespread bone metastases: result of a feasibility, our initial experience. Urol J. 2019; 16(2): 162\u2013167.","journal-title":"Urol J"},{"issue":"5","key":"e_1_3_2_9_2","first-page":"486","article-title":"Factors predicting prostate specific antigen failure following radical prostatectomy: experience with 961 patients","volume":"17","author":"Simforoosh N","year":"2020","unstructured":"Simforoosh N, Dadpour M, Mousapour P, et al. Factors predicting prostate specific antigen failure following radical prostatectomy: experience with 961 patients. Urol J. 2020; 17(5): 486\u2013491.","journal-title":"Urol J"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.21037\/tau-20-1370"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.06.010"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2017.12.24"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.12.009"},{"issue":"2","key":"e_1_3_2_14_2","first-page":"149","article-title":"Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman KE","year":"2020","unstructured":"Hoffman KE, Penson DF, Zhao Z, et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. J Am Med J. 2020; 323(2): 149\u2013163.","journal-title":"J Am Med J"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.1192"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.05.005"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.11.055"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020368"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28303"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-020-03471-x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/03915603221078266"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.005"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2014.10.060"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.11.005"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.12.082"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2020.2.136"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603251322577","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603251322577","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603251322577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:18:43Z","timestamp":1747401523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603251322577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/03915603251322577"],"URL":"https:\/\/doi.org\/10.1177\/03915603251322577","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}